Evanston Pharma Inc was founded in 2003 and rebranded as Evanstoninc LLC in 2012. It initially focused on API sales and recently shifted its focus to consulting and preparation product entry into the US market. The company has helped numerous Chinese companies to gain FDA approval and establish sales for their API products. Additionally, two Chinese companies have successfully entered the US market with their preparation products, with stable sales, through Evanstoninc's agency. One of these companies is a publicly listed firm in Zhejiang, while the other is based in Jiangsu. There is also a Zhejiang-based listed company with a product awaiting FDA on-site inspection and a completed sales contract.
Professional sales experts and senior BD with nearly 40 years of working experience in the pharmaceutical industry, and as the registered agent of domestic companies in the United States, including 25 years in the United States and 15 years in China. We have good connections with major US companies such as Bristol-Myers Squibb, Pfizer, Sandoz, Endo, Novartis, Johnson & Johnson, etc. They are proficient in exporting and selling APIs and preparations from China to the United States, Brazil and other countries, and CRO companies in Business development in China and the United States.
Successfully established Novelstar Pharmaceuticals Inc, a complex company located in New Jersey, USA, and attracted Fosun Pharma’s 20 million USD Series A investment
Biochemical engineering，bachelor of sciences of East China University of Science and Technology （1983）
Licensed Pharmacist （1996 - Now）
Experience: 20+ years in Pharmaceutical / Healthcare Industry focusing on corporate strategy, corporate business development, finance, and commercial operations for generic and branded specialty products
Most recently, Tina was the CEO of Virtus Pharmaceuticals, a niche pharmaceutical company focused on the development of products in generic and specialty markets.
Prior to Virtus, Tina was the CEO of Twi Pharmaceuticals, a Taiwanese pharmaceutical company specializing in the development, manufacturing and commercialization of high barrier generic products with focus on the US and Asia markets.
Prior to TWi, Tina was the Vice President Business Development and Alliance Management of Teva Pharmaceuticals
Tina has served on the boards of Sunrise Pharmaceuticals; Virtus Pharmaceuticals; TWi Pharmaceuticals; Genovi Pharmaceuticals; UNYQ, a design & technology personalization & customization company; Anivive Lifesciences, Inc., a biotech company; Pacific Symphony Orchestra; Chinese Communities Leadership Council
MBA in international finance and marketing from University of Southern California
Experience: 20+ years in pharmaceutical industry with focus on P&L responsibility, Corporate Strategy, Business Development, Sales, Commercial Operations in the Generics / 505(b)(2) / Specialty Pharma / OTC and Active Ingredients space. Extensive international experience working with clients/partners/customers/suppliers across China/India/EU/North & South America.
Recently founded Orspra Pharm LLC, as a virtual venture to identify and develop niche/challenging/potential firstgeneric opportunity products through partnership
Prior to Orspra, Mani was Head of Business development at Tris Pharma Inc, a pharmaceutical company focused on Brand and Generics, with focus on 505(b)(2) and specialty products. He built the entire In. Licensing practice and helped establish relationships with many Chinese companies.
Prior to Tris, Mani was President of Granules USA Inc, a subsidiary of Granules India Ltd which is a vertically integrated pharmaceutical company with interests in Generics / OTC / Active Ingredients. He led the company transition from an API player to Generics player and helped triple the revenue during his time
Prior to Granules, Mani was Director – Marketing for Malladi Drugs & Pharmaceuticals Ltd, India, where he was heading their Sales team while based in India and helped expand in East Asia and Latin America. Later moved to US and helped grow the US/North American market and helped acquire a competition (Novus Fine Chemicals LLC) to double the revenue of the group and bring about a new business model.
MBA from Indian Institute of Management, Ahmedabad, India and a Bachelor’s degree in Food Science & Dairy Technology from College of Dairy Science, Anand, India.
Experience: 25+ years in the pharmaceutical industry; recognized expert in product commercialization and pharmaceutical distribution.
Vinod was CEO at Virtus Pharmaceuticals LLC through from April 2019 to June 2020 and was responsible for providing strategic direction, management oversight and overall business execution which led to a successful exit in May 2020.
Prior to Virtus, Vinod was President of Pharma Channel Consulting to advise on initiatives including acquisition-related DD, set up distribution infrastructure, contracting & pricing, and market commercialization for PE firms and emerging generic manufacturers from India and China.
Prior to Pharma Channel Consulting, Vinod spent 15+ years at McKesson and was the SVP of Generics with 150 employees overseeing sourcing, sales and supply chain for the generics business of US market.
MBA from Case Western Reserve University and a Bachelor's degree in Commerce from Mumbai University.